Profile
Vives Partners is a venture capital firm based in Belgium that focuses on early-stage investments, particularly in university spin-offs and innovative startups. Established in 2004, the firm is initiated by UCLouvain and collaborates closely with other universities and incubators across Europe. Vives Partners maintains a small team of investment professionals who leverage their academic and industry networks to identify and support promising ventures that have the potential to deliver societal impact.
Vives Partners has a multi-sectoral investment strategy, focusing on industries such as biotechnology, healthtech, and technology, with a particular emphasis on projects that deliver a positive societal impact. The firm typically invests in Series A and B rounds with check sizes ranging from $1-5 million. Their funds under management total about €128 million, with their latest being the €70 million VIVES Inter-University Fund.
Notable investments by Vives Partners include ATB Therapeutics - targeted cancer therapy, ViroVet - antiviral treatments for livestock, BiocSol - advanced biopesticides, Generare - molecular data generation, and Bionyra Pharma - next-generation biologics for inflammatory diseases.
Industry
Vives Partners Funds
| Name | Type |
|
|
|
Size | AUM | Launch date |
|---|---|---|---|---|---|---|---|
|
VIVES Inter-University Fund
|
Venture Capital (VC)
|
Biotechnology
Medical Devices
Pharmaceuticals
Technology
Internet of Things (IoT)
HealthTech
|
Series A
Series B
|
Europe
|
$1-5 m
|
—
|
October 2026
|
Contacts
Instant access on the web. Plans from $129/month — see pricing.